Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney)

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 3, 2008, Pages 432-440

  Hammerich, Kai Hans ^a   Ayala, Gustavo A ^a   Wheeler, Thomas M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN;

BIOCHEMISTRY; BLADDER; CANCER DIAGNOSIS; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY; KIDNEY CANCER; PROSTATE; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TESTIS; TESTIS TUMOR; UROGENITAL SYSTEM; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR;

HUMANS; IMMUNOHISTOCHEMISTRY; SENSITIVITY AND SPECIFICITY; UROGENITAL NEOPLASMS;

EID: 40149108470     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62:3-12.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Djavan B, Zlotta A, Kratzik C, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999;54:517-522.
4. Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol. 1998;16:100-105.
5. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663-3667.
6. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13:389-396.
7. Allsbrok WC, Pfeiffer EA. Histochemistry of the prostate. In: Foster CS, Bostwick DG, eds. Pathology of the Prostate. Philadelphia, Pa: WB Saunders Co; 1998:282-303.
8. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis. Washington, DC: Armed Forces Institute of Pathology; 2000. Atlas of Tumor Pathology; 3rd series, fascicle 28.
9. Nadji M, Tabei SZ, Castro A, Chu TM, Morales AR. Prostatic origin of tumors: an immunohistochemical study. Am J Clin Pathol. 1980;73:735-739.
10. Nadji M, Tabei SZ, Castro A, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer. 1981;48:1229-1232.
11. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
12. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619-624.
13. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830.
14. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226.
15. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27:1128-1133.
16. Ernst T, Hergenhahn M, Kenzelmann M, et al. Gene expression profiling in prostatic cancer [in German]. Verh Dtsch Ges Pathol. 2002;86:165-175.
17. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174.
18. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26:926-931.
19. Sanderson SO, Sebo TJ, Murphy LM, Neumann R, Slezak J, Cheville JC. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004;121:220-225.
20. Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene. 1998;17:3301-3308.
21. Angèle S, Falconer A, Foster CS, Taniere P, Eeles RA, Hall J. ATM protein overexpression in prostate tumors: possible role in telomere maintenance. Am J Clin Pathol. 2004;121:231-236.
22. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35:122-128.
23. Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol. 1999;162:1462-1466.
24. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997;43:69-77.
25. Skotheim RI, Korkmaz KS, Klokk TI, et al. NKX3.1 expression is lost in testicular germ cell tumors. Am J Pathol. 2003;163:2149-2154.
26. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate. 2003;55:111-117.
27. Bethel CR, Faith D, Li X, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006;66:10683-10690.
28. Ali TZ, Epstein JI, Bieberich CM, De Marzo AM. NKX3.1 as a new tissue marker of prostatic adenocarcinoma. Presented at: 95th Annual Meeting of the United States and Canadian Academy of Pathology; February 11-17, 2006; Atlanta, Ga. Abstract 582.
29. Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001;61:1563-1568.
30. Kalos M, Askaa J, Hylander BL, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004;60:246-256.
31. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006;236:229-238.
32. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006;66:1521-1534.
33. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-322.
34. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439.
35. Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000;113:383-388.
36. Genega FM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
37. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587.
38. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.
39. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747-754.
40. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
41. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
42. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
43. McKenney JK, Amin MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol. 2005;22:69-87.
44. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28:1373-1378.
45. Petersen OW, van Deurs B. Characterization of epithelial membrane antigen expression in human mammary epithelium by ultrastructural immunoperoxidase cytochemistry. J Histochem Cytochem. 1986;34:801-809.
46. Thomas P, Battifora H. Keratins versus epithelial membrane antigen in tumor diagnosis: an immunohistochemical comparison of five monoclonal antibodies. Hum Pathol. 1987;18:728-734.
47. Ikegami H, Iwasaki H, Ohjimi Y, Takeuchi T, Ariyoshi A, Kikuchi M. Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol. 2000;31:332-340.
48. Pinkus GS, Kurtin PJ. Epithelial membrane antigen - a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol. 1985;16:929-940.
49. Linnenbach AJ, Seng BA, Wu S, et al. Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol. 1993;13:1507-1515.
50. Yang GS, Wang YM, Chen ZD. [The specific expression profile of homeobox gene NKX3.1 mRNA and protein in prostate tissues and its relationship with primary prostate cancer]. Zhonghua Nan Ke Xue. 2006;12:137-140, 144.
51. Korkmaz CG, Korkmaz KS, Manola J, et al. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol. 2004;172:1134- 1139.
52. Brown LM, Pottern LM, Hoover RN, Devesa SS, Aselton P, Flannery JT. Testicular cancer in the United States: trends in incidence and mortality. Int J Epidemiol. 1986;15:164-170.
53. Suster S, Moran CA, Dominguez-Malagon H, Quevedo-Blanco P. Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases. Hum Pathol. 1998;29:737-742.
54. Niehans GA, Manivel JC, Copland GT, Scheithauer BW, Wick MR. Immunohistochemistry of germ cell and trophoblastic neoplasms. Cancer. 1988;62:1113-1123.
55. Ulbright TM. Germ cell neoplasms of the testis. Am J Surg Pathol. 1993;17:1075-1091.
56. Emerson RE, Ulbright TM. The use of immunohistochemistry in the differential diagnosis of tumors of the testis and paratestis. Semin Diagn Pathol. 2005;22:33-50.
57. Jones TD, Ulbright TM, Eble JN, Cheng L. OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res. 2004;10:8544-8547.
58. Biermann K, Klingmuller D, Koch A, et al. Diagnostic value of markers M2A, OCT3/4, AP-2γ, PLAP and c-KIT in the detection of extragonadal seminomas. Histopathology. 2006;49:290-297.
59. Jacobsen GK. Alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in testicular germ cell tumours: a comparison of histologic and serologic occurrence of tumour markers. Acta Pathol Microbiol Immunol Scand A. 1983;91:183-190.
60. Manivel JC, Jessurun J, Wick MR, Dehner LP. Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms. Am J Surg Pathol. 1987; 11:21-29.
61. Beckstead JH. Alkaline phosphatase histochemistry in human germ cell neoplasms. Am J Surg Pathol. 1983;7:341-349.
62. Sigg C, Hedinger C. Atypical germ cells of the testis: comparative ultrastructural and immunohistochemical investigations. Virchows Arch A Pathol Anat Histopathol. 1984;402:439-450.
63. Dekker I, Rozeboom T, Delemarre J, Dam A, Oosterhuis JW. Placental-like alkaline phosphatase and DNA flow cytometry in spermatocytic seminoma. Cancer. 1992;69:993-996.
64. Cummings OW, Ulbright TM, Eble JN, Roth LM. Spermatocytic seminoma: an immunohistochemical study. Hum Pathol. 1994;25:54-59.
65. Huse JT, Pasha TL, Zhang PJ. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta Neuropathol (Berl). 2007;113:87-94.
66. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Upregulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-921.
67. Bailey D, Marks A, Stratis M, Baumal R. Immunohistochemical stainingof germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody. Mod Pathol. 1991;4:167-171.
68. Sonne SB, Herlihy AS, Hoei-Hansen CE, et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch. 2006;449:200-206.
69. Scholer HR, Dressier GR, Balling R, Rohdewohld H, Gruss P. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 1990;9:2185-2195.
70. Guillaudeux T, Mattei MG, Depetris D, Le Bouteiller P, Pontarotti P. In situ hybridization localizes the human OTF3 to chromosome 6p21.3→p22 and OTF3L to 12p13. Cytogenet Cell Genet. 1993;63:212-214.
71. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244-2250.
72. Ulbright TM, Young RH. Seminoma with tubular, microcystic, and related patterns: a study of 28 cases of unusual morphologic variants that often cause confusion with yolk sac tumor. Am J Surg Pathol. 2005;29:500-505.
73. Cheville JC, Rao S, Iczkowski KA, Lohse CM, Pankratz VS. Cytokeratin expression in seminoma of the human testis. Am J Clin Pathol. 2000;113:583-588.
74. Ferreiro JA. Ber-H2 expression in testicular germ cell tumors. Hum Pathol. 1994;25:522-524.
75. Bruce E, Al-Talib RK, Cook IS, Theaker JM. Vacuolation of seminiferous tubule cells mimicking intratubular germ cell neoplasia (ITGCN). Histopathology. 2006;49:194-196.
76. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
77. Latza U, Foss HD, Durkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995;146:463-471.
78. Hittmair A, Rogatsch H, Hobisch A, Mikuz G, Feichtinger H. CD30 expression in seminoma. Hum Pathol. 1996;27:1166-1171.
79. Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190:613-618.
80. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133:446-450.
81. Zamecnik M, Sultani K. Diffuse embryoma with intratubular germ-cell neoplasia. Histopathology. 2004;45:427-429.
82. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498-504.
83. Leroy X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem. 2002;50:283-285.
84. Ramalingam P, Malpica A, Silva EG, Gershenson DM, Liu JL, Deavers MT. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004;28:1499-1505.
85. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol. 1995;177:253-258.
86. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005;18(suppl 2):S51-S60.
87. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer. 1999;83:815-822.
88. Kraggerud SM, Berner A, Bryne M, Pettersen EO, Fossa SD. Spermatocytic seminoma as compared to classical seminoma: an immunohistochemical and DNA flow cytometric study. APMIS. 1999;107:297-302.
89. McMaster M, Zhou Y, Shorter S, et al. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylate. J Immunol. 1998;160:5922-5928.
90. Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol. 2001;20:31-47.
91. Singer G, Kurman RJ, McMaster MT, Shih le M. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol. 2002;26:914-920.
92. Shih IM, Kurman RJ. p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol. 2004;28:1177-1183.
93. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26:1477-1483.
94. Kommoss F, Oliva E, Bittinger F, et al. Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol. 2000;31:1055-1061.
95. Shih IM, Kurman RJ. Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol. 1999;18:144-150.
96. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
97. Bostwick DG, Eble JN. Diagnosis and classification of renal cell carcinoma. Urol Clin North Am. 1999;26:627-635.
98. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
99. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005;18:535-540.
100. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol. 2002;10:332-338.
101. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
102. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537-544.
103. Kumar D, Kumar S, Adrenal cortical adenoma and adrenal metastasis of renal cell carcinoma: immunohistochemical and DNA ploidy analysis. Mod Pathol. 1993;6:36-41.
104. Holthofer H, Miettinen A, Paasivuo R, et al. Cellular origin and differentiation of renal carcinomas: a fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins. Lab Invest. 1983;49:317-326.
105. O'Hara BJ, Paetau A, Miettinen M. Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma. Hum Pathol. 1998;29:119-126.
106. Stopyra GA, Warhol MJ, Multhaupt HA. Cytokeratin 20 immunoreactivity in renal oncocytomas. J Histochem Cytochem. 2001;49:919-920.
107. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol. 2001;32:282-287.
108. Taki A, Nakatani Y, Misugi K, Yao M, Nagashima Y. Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases. Mod Pathol. 1999;12:310-317.
109. Bonsib SM, Bromley C, Lager DJ. Renal oncocytoma: diagnostic utility of cytokeratin-containing globular filamentous bodies. Mod Pathol. 1991;4:16-23.
110. Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen I. Expression of E- and N-cadherin in renal cell carcinomas, in renal cell carcinoma cell lines in vitro and in their xenografts. Int J Cancer. 1995;64:407-414.
111. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697-710.
112. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18:933-940.
113. Wang HY, Mills SE. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29:640-646.
114. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'. Am J Surg Pathol. 2001;25:1485-1492.
115. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2004;121:878-883.
116. Lin ZH, Han EM, Lee ES, et al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol. 2004;17:611-616.
117. Petit A, Castillo M, Santos M, Mellado B, Alcover JB, Mallofre C. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol. 2004;28:676-678.
118. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874-881.
119. Akhtar M, Tulbah A, Kardar AH, Ali MA. Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol. 1997;21:1188-1195.
120. Went P, Dirnhofer S, Salvisberg T, et al. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol. 2005;29:83-88.
121. Martignoni G, Pea M, Chilosi M, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol. 2001;14:760-767.
122. Martignoni G, Pea M, Brunelli M, et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004;17:1455-1463.
123. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76.
124. Anagnostaki E, Skarlos D, Tamvakis N, et al. Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1. Br J Cancer Suppl. 1990;10:52-56.
125. Zorzos J, Zizi A, Bakiras A, et al. Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Eur Urol. 1995;28:251-254.
126. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinomas of the bladder [published online ahead of print June 22, 2007]. J Clin Pathol.